A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
about
Update on rational targeted therapy in AMLSuberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cellsEmerging therapies for acute myeloid leukemia.Myeloid leukemia: are we getting better?Epigenetic synergy between decitabine and platinum derivativesRepositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in OsteoblastsCombinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signalingThe histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells.Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy aloneImpact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.GFI1 as a novel prognostic and therapeutic factor for AML/MDS.Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.Molecular targeting in acute myeloid leukemiaDecitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Crotonoside exhibits selective post-inhibition effect in AML cells via inhibition of FLT3 and HDAC3/6.Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Precision therapy for acute myeloid leukemia.Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines
P2860
Q26766152-CCF5F38E-C670-4918-98E5-14522570DFADQ33566645-4594AFE3-2535-4914-BE90-F4AB04F15CA2Q33576363-CB11FA41-763B-4601-ABE5-B7E1DE89457EQ35054842-80804390-C0DA-48BF-B43E-6EDAEF94DC43Q36053915-C6431F7E-6719-4D05-8974-BDE5E453DDE9Q36225879-959F80CC-2FAD-4121-94C5-2C3753084CF0Q36242646-9714A958-32A7-4E97-844C-E11C0087011BQ36395421-90F43742-E784-44E6-82C6-05967648563BQ36444091-FCF14A5B-7D49-46EC-A27C-1D3814A7F316Q37117964-E907BC16-F63E-4784-B7B0-8F55161DD07CQ37144116-0FE1D9FB-C9ED-4D54-8004-6E77C29B180CQ37301688-8F880BB3-EE80-49AA-9DA2-8E9AEACCB6D7Q37348159-8109C142-12D5-4390-914C-0A7AB1B1631AQ37742267-C4BFEF65-CF76-4BAF-B8BC-E62A5A9B7277Q38572855-7FBECB48-F25F-436F-927A-CB44F8E9F53CQ38833038-03E4489E-55F0-444B-A5B2-46285331AE78Q38946185-00729992-38D6-4DDF-9974-D8D308F47453Q38961023-863D1E8F-620B-433F-8512-A1FA7535D96BQ40022463-FDDE3851-0B0D-4331-BE75-52C24B198EFEQ40377702-37CDDFF3-0749-4EAD-8B90-12222EC75370Q41558732-0BB90FCD-EDD2-48D4-9A96-B4959D158D4CQ41612823-1028F790-EF3D-4A8B-9EA9-9FA8EF815A61Q46246730-13121337-0EEA-419C-8BE6-F14ABFDFCFADQ47099325-DAF80DBC-105F-45CD-83DF-0C850E91247AQ47104275-145F56B7-51D1-4BE7-9F51-21A260CB9A6EQ47559681-FF711257-D51B-4739-AE72-457238A74188Q49167307-E603534D-0E1F-430A-B7B6-D9AEC046E974Q49244147-3C01CDC7-F257-4AF3-9F32-2F2CFD5E9193Q49534332-8D6EDD73-F804-4A13-9CD9-5DDDAF11B7DEQ50128200-3F344B38-B3FB-4CA0-8C06-C915C578C2D5Q51176745-4BA783DB-6EA9-41E9-9F6F-D7F90256BFBEQ51835906-8266CFB0-7E07-49E2-88C2-FAE8BBAA863CQ52641884-FB7897E5-A5F9-4046-B097-B57D161E7288Q52764678-EEA71481-B469-466E-B52F-7C32C2E10FE6Q55433291-61F1533D-4AB8-498C-B9E4-B354E980D2C0Q58776042-F7FACC2F-1444-4E84-9F17-93F4FA80AA98
P2860
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
A phase 1 clinical trial of vo ...... a or myelodysplastic syndrome.
@en
A phase 1 clinical trial of vo ...... a or myelodysplastic syndrome.
@nl
type
label
A phase 1 clinical trial of vo ...... a or myelodysplastic syndrome.
@en
A phase 1 clinical trial of vo ...... a or myelodysplastic syndrome.
@nl
prefLabel
A phase 1 clinical trial of vo ...... a or myelodysplastic syndrome.
@en
A phase 1 clinical trial of vo ...... a or myelodysplastic syndrome.
@nl
P2093
P2860
P356
P1476
A phase 1 clinical trial of vo ...... ia or myelodysplastic syndrome
@en
P2093
Alessandra Tosolini
Allen Yang
Christopher Bredeson
Gregory M Lubiniecki
Ivana Gojo
Joseph E Eid
Lisa A Kujawski
Mark Kirschbaum
Paul Frankel
Peter Marks
P2860
P304
P356
10.1111/BJH.13016
P407
P577
2014-07-08T00:00:00Z